Application of plasma-free replacement liquid composition in preparation of medicine for removing M protein of multiple myeloma

Abstract

The invention discloses an application of a plasma-free replacement liquid composition in preparation of a medicine for removing M protein of multiple myeloma. Plasma exchange treatment can be carriedout on a multiple myeloma case with the plasma-free replacement fluid. The plasma-free replacement liquid composition comprises three parts which are equal in quantity, are independently prepared andare separately used, wherein the three parts are respectively 0.9% normal saline, equilibrium liquid and 4% albumin normal saline, the equilibrium liquid is sodium lactate Ringer's liquid, and the preparation method of the 4% albumin normal saline comprises the step of adding 100ml of 20% albumin into 400ml of normal saline. Compared with the prior art, the blood sedimentation index, the renal function index and the blood high-viscosity state of a patient can be effectively improved compared with those before treatment, and the patient does not have serious adverse reaction after treatment. The application of the plasma-free replacement liquid taking albumin as the main component remarkably reduces the dosage of fresh frozen plasma, and the plasma-free replacement liquid composition has clinical popularization value.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of a plasma-free replacement fluid composition in the preparation of a drug for eliminating multiple myeloma M protein. Background technique [0002] Multiple myeloma (MM) is the second most common blood cancer after non-Hodgkin's lymphoma. Its tumor cells originate from plasma cells in the bone marrow and are classified by WHO as plasma cell myeloma plasma cell neoplasm [1] . It is characterized by abnormal proliferation of bone marrow plasma cells with overproduction of monoclonal immunoglobulins or light chains (M proteins). Multiple myeloma is often accompanied by multiple osteolytic lesions, hypercalcemia, anemia, and kidney damage, which seriously threaten the life, health and quality of life of patients and bring a heavy burden to society [2-5] . When a large amount of M protein passes through the kidney, it can cause acute or chronic renal failure; ...

AI Technical Summary

Problems solved by technology

[0004] Due to the current clinical application of plasma exchange for multiple myeloma patients, the average amount of plasma per replacement is 1500ml, which requires a large amount of fresh plasma supplementation. The clinical situation often shows that the supply of fresh frozen plasma (FFP) is in short supply and the patient's expenditure is too high. Therefore, clinical fewer applications

The use of hydroxyethyl starch can alleviate the shortage of plasma resources in hospitals to a certain extent, but adverse reactions such as allergic reactions and kidney damage may occur after the use of hydroxyethyl starch, which affects the prognosis of patients and limits its clinical application effect [13]

Images